Scleroderma, Diffuse research hub

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

This study is testing a new treatment, rapcabtagene autoleucel, against an existing one, rituximab, for severe diffuse scleroderma. We want to see if the new treatment is safe and effective in helping people with this condition and improving their symptoms.